Seronegative arthritis: when the tests are negative and the pain is still loud.

Your rheumatoid factor and anti-CCP came back negative, your joints still hurt, and nobody has explained the gap. Here is one explanation worth knowing.

This page is about understanding the condition and the role the brain and nervous system can play in it. It is not a diagnosis. Your own clinicians know your case.

What seronegative arthritis is

Arthritis means inflammation in a joint. When a rheumatologist suspects an inflammatory arthritis, two blood tests are usually ordered: rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA, often called anti-CCP). If both are negative but the joints are clearly inflamed, the label is seronegative arthritis. The word simply means 'negative in the serum', the liquid part of the blood.

Seronegative arthritis is a starting point rather than a final answer. Over months or years it may declare itself as seronegative rheumatoid arthritis, psoriatic arthritis, a spondyloarthritis, reactive arthritis or something else. On the whole, the course is milder than in people with positive RF or ACPA, with less joint damage over time.

Treatment targets the inflammation with anti-inflammatory and disease-modifying medicines. The puzzle starts when the blood markers and ultrasound say the inflammation is quiet, and the pain is not.

The neuroplastic contribution

Neuroplastic symptoms are real symptoms generated by learned pathways in the brain and nervous system rather than by ongoing damage or disease in the body. Pain is an alarm the brain produces to protect you. After months of genuine joint inflammation, that alarm can become sensitized, so it fires more easily and more loudly than the tissue warrants. The pain is not imaginary and it is not 'all in your head'. It is a nervous system that has learned to be on guard, and because the brain can change, that learning can be reversed.

The ATNS Index of Neuroplastic Symptoms does not say seronegative arthritis is neuroplastic. Its position is that the condition is not caused by neuroplastic symptoms, but that in some patients they contribute to the overall symptom load. It flags two situations where that contribution is particularly likely:

• The course over time is not typical. Pain spreads to joints that were never inflamed, or keeps rising while the inflammation markers fall.
• The response to treatment is not typical. Medicines that have clearly calmed the swelling leave the pain, fatigue and stiffness roughly where they were.

In those cases two things are true at once: a real inflammatory arthritis that needs rheumatology care, and a learned layer of pain that medication for inflammation cannot reach. Our explainer on central sensitization describes how that layer forms.

What the research shows

A 2026 review of shared mechanisms across fibromyalgia, osteoarthritis and inflammatory arthritis concluded that features of central sensitization have been documented in rheumatoid and psoriatic arthritis, and that pain in these conditions often does not track with inflammation or structural damage.

A systematic review of fibromyalgia and central sensitization in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis found that these overlapping, centrally driven pain patterns are common across the inflammatory arthritides, and it cautions that fibromyalgia, central sensitization and nociplastic pain are related ideas rather than one and the same.

Axial spondyloarthritis, the best-studied seronegative arthritis, has been looked at directly. A study of the Central Sensitisation Inventory, a questionnaire about signs of a sensitized nervous system, found that more than half of people with axial spondyloarthritis scored in the sensitized range, and the authors proposed it as a practical first screen in clinic.

A study using quantitative sensory testing (measured responses to touch, pressure and temperature) in several rheumatic diseases found pain from normally harmless touch in about 15% of people with axial spondyloarthritis and in none of the healthy controls. These sensory changes did not track with disease activity, disease duration or blood markers of inflammation.

Most of this work is cross-sectional, so it shows overlap rather than cause. But it supports the index's advice: when the pain and the inflammation stop matching, look at the nervous system.

Signs the brain may be part of the picture

• Your inflammation markers (CRP, ESR) and joint ultrasound have improved, but your pain has not.
• Pain has spread to areas that were never swollen, or you hurt 'all over' on bad days.
• Fatigue, poor sleep, brain fog and sensitivity to noise or light have joined the joint pain.
• Symptoms swing with stress, conflict or worry more than with activity or weather.

None of these prove anything on its own. Together they describe a nervous system that is doing more of the work than the joints, which is a pattern that responds to a different kind of help. Our guide to hurt versus harm explains why that distinction changes what you do next.

A solution that addresses it

There is an approach that addresses the brain's contribution to pain, often called pain reprocessing or symptom reprocessing. It combines clear education about neuroplastic symptoms, somatic tracking (observing sensations with curiosity instead of alarm), lowering fear and threat around movement, a graded return to activity, emotional awareness and expression, and acceptance and commitment skills. Trained clinicians deliver it, and it is increasingly available through digital programs. It sits alongside rheumatology care rather than replacing it.

Cindra is a daily AI companion built around these approaches, with daily check-ins, short practices and plain-language lessons, for people whose symptoms have a neuroplastic component. If your arthritis is being treated and the pain still runs ahead of the inflammation, you can join the waitlist.

What to do next

1. Keep your rheumatology follow-up and your medication. Seronegative arthritis is a real inflammatory disease, and the first job is to keep the inflammation controlled. Do not stop or change treatment on your own.
2. Ask your rheumatologist a direct question: 'Does my current pain match my current inflammation?' If the answer is no, ask whether a neuroplastic or centrally sensitized pattern could be contributing.
3. If it might be, start learning. Read about the three types of pain so you can tell inflammatory pain from learned pain in your own body.
4. Begin practising.

Seek prompt medical care for a single hot, red, very swollen joint with fever, which can mean infection, and for any new weakness, numbness or unexplained weight loss.

This article is for general education and is not medical advice, and it does not diagnose or treat any condition. Persistent symptoms deserve a proper medical assessment to rule out disease or injury before a neuroplastic explanation is considered. If your symptoms are new, changing, or come with red-flag signs such as fever, unexplained weight loss, numbness or weakness, chest pain, or loss of bladder or bowel control, see a clinician promptly.